跳至主要内容
临床试验/NCT04358770
NCT04358770已完成1 期

Single Exposure Bioequivalence Study to Evaluate the Vasoconstriction Activity of Topically Applied Cloderm® (Clocortolone Pivalate) 0.1% Cream and Clocortolone Pivalate 0.1% Cream (Taro Pharmaceuticals) in Healthy Male and Female Volunteers With Normal Skin Under Occlusive Conditions.

Taro Pharmaceuticals USA1 个研究点 分布在 1 个国家目标入组 124 人开始时间: 2018年3月2日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
124
试验地点
1
主要终点
AUEC0-24 (area under the effect curve)

研究概览

简要总结

To compare pharmacodynamic vasoconstriction response profile of Clocortolone Pivalate 0.1% Cream and Cloderm® (Clocortolone Pivalate) 0.1% Cream in normal skin of healthy male and female adults

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Health Services Research
盲法
None

入排标准

年龄范围
18 Years 至 35 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Normal or clinically insignificant dermatological history the Screening visit and Day 1dosing;

排除标准

  • Female subjects who were pregnant, nursing, or planning to become pregnant during study participation;
  • History of hypersensitivity to the study products or any topical or systemic corticosteroids;

研究组 & 干预措施

Test

Experimental

Clocortolone Pivalate Cream, 0.1%

干预措施: Clocortolone Pivalate (Drug)

Reference

Active Comparator

Cloderm® (clocortolone pivalate) Cream, 0.1%

干预措施: Clocortolone Pivalate (Drug)

结局指标

主要结局

AUEC0-24 (area under the effect curve)

时间窗: 24 hours

value for the blanching intensity vs. time profile

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验